Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Impact of Dietary Fibre Supplementation on Gut Symptoms in Healthy Participants (KiVa)

7 mai 2026 mis à jour par: Anne-Maria Pajari, University of Helsinki

The Effect of Dietary Fibre Supplementation on Gastrointestinal Symptoms in Healthy Participants - KiVa-trial

Fibres found in food are mainly carbohydrates that are not broken down or absorbed during human digestion but instead pass to the colon to be fermented by microbes. Gases produced during bacterial fermentation (hydrogen, methane, and carbon dioxide), can cause unpleasant gastrointestinal symptoms in some individuals, such as bloating, flatulence, and stomach pain. Gas production varies between individuals and is influenced by the chemical structure of dietary fibres, the gut microbes' ability to ferment fibre, intestinal pH, and the transit time of intestinal contents. This randomized clinical trial in healthy adults will investigate how individual variations in the microbiome influence the level of gastrointestinal (GI) symptoms induced by different fibre types during short-term exposure.

Aperçu de l'étude

Description détaillée

The objective of this dietary intervention is to examine the effects of different dietary fibre types on gastrointestinal symptoms in apparently healthy adults and to investigate how these effects relate to the composition and functional capacity of the gut microbiota.

The study is designed as a randomized, crossover intervention trial with a total duration of approximately 6 weeks. A 5-day run-in phase is carried out to stabilize baseline dietary patterns and ensure adherence to study procedures. During the intervention, each participant consumes 3 different fibre-rich products, with each product administered for 4 consecutive days (referred to as a "fibre period"). Each fibre period is separated by a 10-day washout period.

Participants (n=28) are apparently healthy adult males and females aged 18-65 years who experience gastrointestinal/ digestive discomfort during or after eating. Individuals without such symptoms are unlikely to exhibit measurable responses, which would limit the ability to address the study's primary research questions.

During the 4-day fibre period, the daily fibre dose provided by the study product is 20 g for women and 25 g for men (corresponding to 2.5 g of fibre per MJ of energy intake, assuming daily energy intake of 8 MJ for women and 10 MJ for men). During the trial, participants consume three structurally different types of dietary fibre: cellulose (poorly fermentable fibre; microcrystalline cellulose), beta-glucan rich fibre (oat bran-based fibre product), and arabinoxylan rich fibre (rye bran-based fibre product). Participants are randomly assigned into one of the six predefined intervention sequences, which represent all possible orders of exposure to the 3 fibre products. Sequence allocation will be generated prior to enrolment, and participants will receive each fibre-rich test product in a randomized order. Participants are instructed to keep the rest of their diet as habitual as possible during the study. Regular use of dietary supplements must be discontinued for the study duration

Participants report their daily GI symptoms as well as perceived stress and mood through a symptom questionnaire using a mobile app. A total of nine GI symptoms are reported (i.e., stomach/ abdominal pain, stomach cramps, bloating, flatulence, borborygmus, nausea, heartburn, discomfort in the upper abdomen/ unpleasant sensation of fullness following eating, a sudden need to defecate), and their severity of symptoms is assessed on a 0-100 VAS scale. Participants report daily the number of bowel movements through the online form, as well as their daily amount of physical activity. In addition, physical activity is assessed using an accelerometer. Dietary intake is assessed by food records (3-day food records during the run-in period and 2-day food records during each fibre period).

Stool samples are used for the analysis of the gut microbiota and metabolome. Additionally, the the effects of different fibre types on metabolic profiles in blood, urine, and stool samples (including SCFAs), as well as on gases in exhaled breath will be analysed.

Type d'étude

Interventionnel

Inscription (Estimé)

28

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Uusimaa
      • Helsinki, Uusimaa, Finlande

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • healthy male and female
  • aged 18-65 years
  • experience gastrointestinal discomfort during or after eating
  • willing to commit to the 6-week study period and follow the study schedule.

Exclusion Criteria:

  • Body mass index ≤ 18.5 or ≥ 35 kg/m².
  • Inflammatory bowel diseases, irritable bowel syndrome (IBS), celiac disease, endocrine or lipid metabolism disorders, liver or kidney diseases, cancer within the past 5 years, eating disorders.
  • Medication for gastrointestinal symptoms, bowel function, diabetes, or hypercholesterolemia.
  • Regular or recent use of antibiotics (within the last 3 months).
  • Food allergies to the ingredients of the study products.
  • Heavy, long-duration exercise several times a week.
  • Smoking, use of snus or nicotine pouches.
  • Planned or ongoing pregnancy or breastfeeding.
  • In addition, the site-specific principal investigator may exclude a person due to any illness, medication, or factor they deem relevant for the participant's health and safety or for the conduct of the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Cellulose
poorly fermentable fibre, "negative control"
Microcrystalline cellulose; daily dose of fibre from the study product 20 g for females and 25 g for males on 4 consecutive days
Expérimental: Oat fibre
fibre-rich product from oat bran
Oat bran-based fibre product; daily dose of fibre from the study product 20 g for females and 25 g for males on 4 consecutive days
Expérimental: Rye fibre
fibre-rich product from rye bran
Rye bran-based fibre product; daily dose of fibre from the study product 20 g for females and 25 g for males on 4 consecutive days

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Intensity of gastrointestinal symptoms, total score
Délai: 6 weeks Differences between the fibre periods and fibre periods and run-in period will be compared.
The composite score of the intensity of individual gastrointestinal symptoms reported on a VAS scale by the participants.
6 weeks Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of stomach/ abdominal pain
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced stomach/ abdominal pain reported on a VAS scale from zero (no pain) to 100 (very intense pain) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of bloating
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced bloatingreported on a VAS scale from zero (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of stomach cramps
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared
Intensity of experienced stomach cramps reported on a VAS scale from zero (no pain) to 100 (very intense pain) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared
Intensity of flatulence
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced flatulence reported on a VAS scale from zero (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of borborygmus
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced borborygmus reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of nausea
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced nausea reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of heartburn
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced heartburn reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of discomfort in the upper abdomen or unpleasant sensation of fullness following eating
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced discomfort or unpleasant sensation reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of a sudden need to defecate
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Intensity of experienced discomfort or unpleasant sensation reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Composition and function of gut microbiome
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Microbiota-related analyses of the collected stool samples are carried out using DNA-based methods
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Number of bowel movements
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Number of bowel movements reported by participants on daily basis using a mobile app.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Breath gases
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Hydrogen and methane measured from exhaled breath samples during run-in and fibre periods.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Fecal and blood SCFA
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Analysis of short chain fatty acids (SCFA) from stool and blood samples
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Dietary intake
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
The intake of dietary fibre and nutrients calculated from food records during run-in and fibre periods.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Physical activity
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Level of physical activity and inactivity determined using an accelerometer during run-in and fibre periods.
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Metabolomics from feces, blood and urine
Délai: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
Targeted/untargeted analysis of fecal, blood and urine metabolome
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

17 août 2026

Achèvement primaire (Estimé)

30 septembre 2026

Achèvement de l'étude (Estimé)

30 septembre 2026

Dates d'inscription aux études

Première soumission

7 mai 2026

Première soumission répondant aux critères de contrôle qualité

7 mai 2026

Première publication (Réel)

14 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

14 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • FIBRE-MATCH Helsinki Pilot
  • 101161484 (Autre subvention/numéro de financement: European Innovation Council (EIC))

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Data sharing in agreement with the EU General Data Protection Regulation

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner